Aprea Therapeutics Q4 EPS $(0.64) Vs. $(4.05) YoY
Portfolio Pulse from Benzinga Newsdesk
Aprea Therapeutics reported a Q4 EPS of $(0.64), showing a significant improvement from the $(4.05) EPS reported in the same quarter last year.
March 26, 2020 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aprea Therapeutics reported a Q4 EPS of $(0.64), a significant improvement from $(4.05) YoY, indicating better financial performance.
The improvement in EPS from $(4.05) to $(0.64) suggests that Aprea Therapeutics is managing its expenses better or generating more revenue, which is a positive sign for investors. This could lead to a short-term increase in stock price as the market reacts to the improved financial performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100